ライフサイエンスコーパス: allograft failure

1 ch may lead to chronic humoral rejection and allograft failure.

2 f anti-HLA antibodies plays a role in kidney-allograft failure.

3 e of chronic rejection, the primary cause of allograft failure.

4 r of alloantibody sensitization after kidney allograft failure.

5 emodeling, which may be one cause of chronic allograft failure.

6 el at retransplant and subsequent pancreatic allograft failure.

7 initial episodes of Gram-negative BSI before allograft failure.

8 tion and a lower risk of death, but not with allograft failure.

9 The primary endpoint was 90-day allograft failure.

10 lated that autoantibodies may play a role in allograft failure.

11 detect clinically significant differences in allograft failure.

12 er, prolonged cold storage can contribute to allograft failure.

13 e analyses for the primary outcome of kidney allograft failure.

14 the former also contribute significantly to allograft failure.

15 mg), five patients (55.5%) experienced renal allograft failure.

16 ry T cells that could favorably prevent late allograft failure.

17 mpered by recurrent infection and subsequent allograft failure.

18 nd progression of the disease often leads to allograft failure.

19 ther a linear nor nonlinear association with allograft failure.

20 study the association of BP and the time to allograft failure.

21 ar immunity is the reputed mechanism of lung allograft failure.

22 or death censored graft survival and chronic allograft failure.

23 ased risk for humoral sensitization or renal allograft failure.

24 Chronic rejection is now the major cause of allograft failure.

25 y disease is the major cause of late cardiac allograft failure.

26 factor for the development of chronic renal allograft failure.

27 rstood process and the primary cause of late allograft failure.

28 sked whether aPA are a risk factor for early allograft failure.

29 ent for the prevention of intrahepatic islet allograft failure.

30 t an ideal agent for the prevention of islet allograft failure.

31 disease were identified as risk factors for allograft failure.

32 are an important risk factor for early renal allograft failure.

33 h acute vascular rejection and early cardiac allograft failure.

34 ntify those patients at high risk for future allograft failure.

35 not prevent progressive chronic-type cardiac allograft failure.

36 t elements that ultimately result in chronic allograft failure.

37 important role in the development of chronic allograft failure.

38 been hypothesized to be one cause of chronic allograft failure.

39 ephropathy is associated with a high rate of allograft failure.

40 survival trajectories and the likelihood of allograft failure.

41 ntion is essential to decrease mortality and allograft failure.

42 rejection (ABMR) is a major cause of kidney allograft failure.

43 opathy (BKN) is an important cause of kidney allograft failure.

44 ably the most important cause of late kidney allograft failure.

45 on are associated with alloimmune injury and allograft failure.

46 us (HCMV) infection is associated with renal allograft failure.

47 ced hepatic fibrosis, necroinflammation, and allograft failure.

48 splantation and is associated with long-term allograft failure.

49 increases delayed graft function and kidney allograft failure.

50 nflammation are major contributors to kidney allograft failure.

51 nd predicts functional decline, and eventual allograft failure.

52 ion did not alter rejection-free survival or allograft failure.

53 iatric cardiac allograft that contributes to allograft failure.

54 t complication of kidney transplantation and allograft failure.

55 only is associated with an increased risk of allograft failure.

56 ciated with composite risk of death or liver allograft failure.

57 and ischemic glomeruli at 5 years predicted allograft failure.

58 cute rejection and is associated with kidney allograft failure.

59 determine whether such changes predict late allograft failure.

60 ntrol for population age structure and renal allograft failure.

61 The primary outcome was death-censored allograft failure.

62 The secondary outcome was pancreas allograft failure.

63 tes of infections, malignancies, and chronic allograft failure.

64 ch inflammation, ADVN does not often lead to allograft failure.

65 form a traditional CBPS in predicting kidney allograft failure.

66 y outcomes included death and death-censored allograft failure.

67 ejection (ABMR) is a leading cause of kidney allograft failure.

68 iation of prerenal and intrinsic acute renal allograft failure.

69 ogic lesions, and a risk predictor of kidney allograft failure.

70 bular atrophy (IF/TA), is a leading cause of allograft failure.

71 ft arteriosclerosis (GA), the major cause of allograft failure.

72 e the primary outcomes of death and death or allograft failure.

73 span, defined as the time free from death or allograft failure.

74 ding to rapidly progressive and irreversible allograft failure.

75 rejection remains the major cause of corneal allograft failure.

76 associated with increased risk of long-term allograft failure.

77 e strongly and independently associated with allograft failure.

78 ing centers to reduce costs and incidence of allograft failure.

79 ignificantly improve prediction of long-term allograft failure.

80 olic hypertension (SHT) are risk factors for allograft failure.

81 increases delayed graft function and kidney allograft failure.

82 ion therapy abolishes the disparity in renal allograft failure.

83 and microvasculature injury were at risk of allograft failure.

84 ospitalization with fever within 6 months of allograft failure.

85 between delayed graft function and long-term allograft failure.

86 tion with histology of AMR (AMRh) and kidney allograft failure.

87 linical transplantation contributes to islet allograft failure.

88 tment of dnDSA-positive patients can prevent allograft failure.

89 NETs) have been implicated in liver and lung allograft failures.

90 esponses are responsible for the majority of allograft failures.

91 ic conversion; 11 patients experienced renal allograft failure (10 underwent a repeat kidney transpla

92 Of the 60 patients, three had allograft failure, 19 died with a functioning graft, and

93 jects including 125 cases of intrinsic acute allograft failure, 27 prerenal graft failures, 118 patie

94 d 170 AA) eliminated the racial disparity in allograft failure (5.7% vs 9.4%, P = 0.8248, hazard rati

95 pAFR: HR 1.90 (1.46-2.48), P = 2.40E-06) and allograft failure (AA: HR 1.52 (1.18-1.97), P = .001; pA

96 Early allograft failure accounts for approximately 25% of deat

97 ith delayed graft function but not all-cause allograft failure (adjusted hazard ratio 1.01, 95% CI 0.

98 dence interval [CI] 1.74-1.92) and all-cause allograft failure (adjusted hazard ratio [aHR] 1.11, 95%

99 Identification of risk factors for renal allograft failure after an episode of acute antibody-med

100 egression model to identify risk factors for allograft failure after C4d+ acute AMR.

101 s been long recognized as a leading cause of allograft failure after kidney transplantation, the cell

102 in the TLR2 gene have increased the risk of allograft failure after liver transplantation for chroni

103 or the predisposition of patients to develop allograft failure after liver transplantation for chroni

104 he primary outcome was time to death or lung allograft failure after lung transplant.

105 ctors that predispose patients to pancreatic allograft failure after renal retransplantation.

106 Additionally, IA was associated with 1-year allograft failure (aHR, 3.37 [95% CI, 1.96-5.77], P < .0

107 e of recipient metabolic rate to the rate of allograft failure among 239 recipients of cadaveric rena

108 ce with medication is a major cause of renal allograft failure among adult renal transplant patients.

109 mate the effect of ESA hyporesponsiveness on allograft failure and all-cause mortality.

110 AV) remains the most prevalent cause of late allograft failure and cardiac mortality.

111 Associations of transplant type with kidney allograft failure and death (multivariable-adjusted haza

112 = 3237) was associated with greater risks of allograft failure and death compared with a CNI-based re

113 ransplant diarrhea is associated with kidney allograft failure and death, but its etiology remains un

114 kidney disease and is associated with early allograft failure and death.

115 in a significantly increased risk of kidney allograft failure and death.

116 y disease (CKD) and is associated with early allograft failure and death.

117 d rejection (AMR) is a major cause of kidney allograft failure and demonstrates different properties

118 Addition of donor PLNC prevent islet allograft failure and leads to recipient chimerism for a

119 R2 Arg753Gln polymorphism is associated with allograft failure and mortality after liver transplantat

120 hazard ratios (95% confidence interval) for allograft failure and mortality after transplantation we

121 ody-mediated rejection is a leading cause of allograft failure and mortality in pediatric solid organ

122 is associated with an increased incidence of allograft failure and mortality, the results of this stu

123 ansplantation ESA response and its effect on allograft failure and mortality.

124 review of 29 consecutive patients with renal allograft failure and nephrectomy.

125 significant risk factor for kidney and liver allograft failure and patient mortality.

126 20-3.89, P=0.01), but the rates of recipient allograft failure and recipient mortality across donor B

127 and 2006 and assessed the effects of RLN on allograft failure and recipients' survival.

128 hesis that podocyte depletion contributes to allograft failure and reduced allograft half-life.

129 Kidney allograft failure and return to dialysis carry a high ri

130 efined as duration of dialysis between first allograft failure and second transplantation, and clinic

131 omes in 300 consecutive patients with kidney allograft failure and survival of more than 30 days afte

132 ted hazard ratios (HRs) for death, all-cause allograft failure, and allograft failure excluding death

133 m surgery, immunosuppression withdrawal with allograft failure, and retained endovascular tissue.

134 r graft survival than patients who had prior allograft failure as a result of acute rejection (P < .0

135 ariate analysis were performed using chronic allograft failure as the outcome of interest.

136 d percentage of ischemic glomeruli predicted allograft failure at 5 years independent of all Banff sc

137 or = 20%) were significantly associated with allograft failure at 5 years.

138 th IFN-gamma:IL-5 ratios > or = 15 developed allograft failure at 6 months (sensitivity 100%, specifi

139 to 12 hr showed an adjusted absolute risk of allograft failure at 90 days of 17.3% (odds ratio 1.84),

140 ged cold ischemia interact to increase liver allograft failure at 90 days.

141 There was a higher rate of allograft failure attributable to rejection in CHD HTs o

142 Excluding early allograft failure because of primary graft nonfunction o

143 diagnosis and 21 days later, died from liver allograft failure because of recurrent lymphoma.

144 208 renal transplant recipients with primary allograft failure between 1985 and 1995 were followed fr

145 related relative cost with observed/expected allograft failure between centers, excluding small cente

146 d returned to long-term dialysis after renal allograft failure between January 1994 and December 2004

147 There was no difference in allograft failure between transplants from donors with i

148 available literature on the causes of kidney allograft failure, both early and late, both nonimmune a

149 available literature on the causes of kidney allograft failure, both early and late, both nonimmune a

150 of the tempo and intensity of chronic renal allograft failure, but also a potent modulator of fundam

151 enal transplant recipients increases risk of allograft failure, but BKPyV-specific therapies are not

152 CYP3A5 genotype had no effect on allograft failure, but CYP3A5 expressers exhibited a sig

153 PyVAN) constitutes a serious cause of kidney allograft failure, but large-scale data in pediatric ren

154 We conclude that AMR may cause allograft failure, but that the diagnosis requires a mul

155 adjustment for DGF, the within-pair ORs for allograft failure by 1 yr were 1.92 (95% CI 1.33 to 2.77

156 Early allograft failure by L-GrAFT 7 was lower in HMP-O 2 , su

157 the relative risk for development of chronic allograft failure (CAF) by 27% (risk ratio [RR] 0.73, P<

158 factor for the development of chronic renal allograft failure (CAF), which is a major cause of late

159 secondary to acute rejection (AR) or chronic allograft failure (CAF).

160 pendent effect on the development of chronic allograft failure (CAF).

161 ronic vascular rejection, a leading cause of allograft failure, can be inhibited by pravastatin in a

162 combinatorial immunosuppression regimens and allograft failure cause significant morbidity and mortal

163 t failure from any cause including death and allograft failure censored for patient death defined by

164 as 0.83 (95% CI, 0.62-1.10; P = .19) and for allograft failure censored for patient death was 0.78 (9

165 CAV) is the preeminent cause of late cardiac allograft failure characterized histologically by concen

166 e similar longitudinal risk of mortality and allograft failure compared with tacrolimus-based regimen

167 In the event of a composite allograft failure, damage to the recipient tissues may m

168 ents had significantly higher risk of kidney allograft failure (DD-KA: aHR (1.53) 2.20(3.17) ; LD-KA:

169 All subjects were followed until allograft failure, death, or December 31, 1992, whicheve

170 Time to allograft failure (defined as death, return to dialysis,

171 were death censored graft survival, chronic allograft failure, delayed graft function, and acute rej

172 de novo collapsing glomerulopathy leading to allograft failure developed in the third patient, who ha

173 Most patients with uncomplicated chronic allograft failure do not require allograft nephrectomy (

174 In late allograft failure, donor-specific antibody deposits comp

175 Three died from allograft failure due to recurrent HCV.

176 d with a 52 percent reduction in the risk of allograft failure during the first year after transplant

177 The reduction in the rate of allograft failure during the first year was attenuated w

178 for death, all-cause allograft failure, and allograft failure excluding death as a cause (competing

179 y], but ADPKD associated with a lower HR for allograft failure excluding death as a cause [0.85 (0.79

180 .34 to 1.81), respectively, and with HRs for allograft failure excluding death as a cause of 1.20 (1.

181 virus, a human polyomavirus associated with allograft failure following kidney transplantation.

182 The adjusted relative risk (RR) of allograft failure for a 15-kg increase in recipient body

183 The relative rate of allograft failure for patients who received a transplant

184 t analyses were performed for death-censored allograft failure for the overall cohort, then separatel

185 d with a lower multivariate adjusted risk of allograft failure from any cause including death (hazard

186 Kidney allograft failure from any cause including death and all

187 The adjusted hazard ratios of allograft failure from any cause including death was 0.8

188 en associated with increasing rates of renal allograft failure from cadaveric donors, independent of

189 s associated with recovery or progression to allograft failure from chronic rejection (CR) were studi

190 inotransferase (P<0.03) were associated with allograft failure from CR.

191 onths after biopsy, three patients developed allograft failure from subsequent acute rejection.

192 The relationship between cost and kidney allograft failure has not been fully investigated in the

193 of transplant recipients after primary renal allograft failure has not been well studied.

194 Rs with CAIFIs had higher 1-y death-censored allograft failure (hazard ratio 1.6 5.1 16.4 , P = 0.006

195 nts, infection/multisystem organ failure and allograft failure (hazard ratio = 1.08 per year incremen

196 er lung transplantation and reduced risk for allograft failure (hazard ratio, 0.36; 95% CI, 0.13-0.98

197 ip was associated with higher death-censored allograft failure (hazard ratio, 1.05; 95% CI, 1.01-1.10

198 eys with WIT>48 minutes had a higher risk of allograft failure (hazard ratio, 1.23; 95% CI, 1.07 to 1

199 nfidence interval, 2.46-12.15; P < .001) and allograft failure (hazard ratio, 5.58; 95% confidence in

200 an estimate of the BKPyV-associated risk of allograft failure (hazards ratio = 2.01) without confoun

201 eatment was associated with a higher risk of allograft failure (hazards ratio, 2.01; 95% confidence i

202 ationship between the cause of primary renal allograft failure, hemoglobin A1c (HbA1c) or fasting C-p

203 ed the significance of hypertension in renal allograft failure; however, these studies have been comp

204 P<0.01) and no difference in death-censored allograft failure (HR 1.09, P=0.62), whereas recipients

205 Recurrent disease increased the risk of allograft failure (HR 2.36, 95% CI 1.28-4.32, P=0.0056).

206 [95% CI], 1.03 to 1.26; P<0.01) and death or allograft failure (HR, 1.18; 95% CI, 1.09 to 1.28; P<0.0

207 registry data, we studied time to all-cause allograft failure in 8092 patients 12 years or older, tr

208 Allograft failure in African-Americans remains higher th

209 risk of posttransplant deceased donor kidney allograft failure in an adult recipient.

210 levels of CRP are associated with subsequent allograft failure in cardiac transplant recipients.

211 t risk factor for the development of chronic allograft failure in Caucasians (RR 1.29 for ages 50-64,

212 lity of the iBox to predict long-term kidney allograft failure in children, with performances similar

213 ate cohort predicts death-censored long-term allograft failure in DSA+ patients regardless of MFI, an

214 with more aggressive recurrent HCV and early allograft failure in HCV-positive liver transplant recip

215 Renal fibrosis is the most common cause of allograft failure in kidney transplantations.

216 enotypes play important roles in the time to allograft failure in kidneys transplanted from deceased

217 , progression, and severity of chronic renal allograft failure in patients with elevated serum creati

218 for both humoral allosensitization and renal allograft failure in situations of HLA-Bw4 incompatibili

219 157, 67 whites and 90 AA) had lower rates of allograft failure in the absence of AL induction (14.9%

220 risk models were used to assess for risk of allograft failure in the presence of death as a competin

221 There were six renal allograft failures in the nonsensitized group but none i

222 of 4000 patients, candidate determinants of allograft failure including donor, recipient and transpl

223 The risk of allograft failure increased 36% for every 2-fold increas

224 irmed that there is an association of BP and allograft failure independent of renal function.

225 th acute-on-chronic liver failure or primary allograft failure is a preferable candidate for this pro

226 Kidney allograft failure is a serious condition as it implies t

227 Kidney allograft failure is a serious condition, as it implies

228 Predicting long-term kidney allograft failure is an unmet need for clinical care and

229 The return to dialysis after allograft failure is associated with increased morbidity

230 Finally, death due to allograft failure is associated with the presence of de

231 Prevention of acute allograft failure is consistent with known immunomodulat

232 The pathophysiology of allograft failure is not fully understood.

233 ONALE: The predominant cause of chronic lung allograft failure is small airway obstruction arising fr

234 antibody-mediated rejection (AMR) and kidney allograft failure is well established.

235 tion, which is the most common cause of late allograft failure, is in part caused by an ongoing immun

236 hough perioperative CD154 blockade prevented allograft failure, it did not reduce allograft vasculopa

237 culate the cumulative risk of death-censored allograft failure may overestimate the risk of failure e

238 were accounted for in the adjusted cost and allograft failure models, they are unlikely to explain t

239 pathy (CAV) is a leading contributor to late allograft failure, mortality, and morbidity after heart

240 Allograft failure occurred in 20 (37.7%) cases, and 14 (

241 lure during follow-up, accounting for 69% of allograft failures occurring after 2.5 years after trans

242 1 reached the combined secondary endpoint of allograft failure or death (9.4 vs. 35.5%, P=0.01); in a

243 dently associated with allograft loss due to allograft failure or death (hazard ratio [HR], 2.52; 95%

244 survival benefit in the combined endpoint of allograft failure or death.

245 iously hemodialyzed patients did not predict allograft failure or success (P=0.3766).

246 after kidney transplantation and may lead to allograft failure or urosepsis.

247 ents older than 70 years had a lower risk of allograft failure (P < 0.01 for each comparison); result

248 DSA+ = TSA+ patients had increased risk of allograft failure (P = .0025) and AMR (P = .02) compared

249 decreased length of stay (P = 0.001), kidney allograft failure (P = 0.012), and dialysis duration (P

250 o graft failure, CRP level was predictive of allograft failure (P:=0.003).

251 he time of transplantation experienced early allograft failure (P=0.0022).

252 d decreased length of stay (p=0.001), kidney allograft failure (p=0.012), and dialysis duration (p=0.

253 er allografts may increase cold ischemia and allograft failure, particularly with livers from older d

254 t 1 year had an adjusted rate ratio (RR) for allograft failure per 10 mL/min (0.17 mL/s) of 0.74 (95%

255 methodology, can offer insight into chronic allograft failure phenotypes and provide prognostic info

256 between relative cost and observed/expected allograft failure (r = 0.096, P = 0.22).

257 in mortality (HR 0.98, P=0.83) but a higher allograft failure rate (HR 1.93, P<0.01).

258 centers with higher than expected costs and allograft failure rates (lower performing) and centers w

259 ients with IgAN or vasculitis had the lowest allograft failure rates.

260 is associated with a small increased risk of allograft failure regardless of open or laparoscopic app

261 ity (3.7% vs 3.8%; P = 0.788), 1-year kidney allograft failure/rejection (16.7% vs 16.8%; P = 0.897),

262 for mortality, rehospitalization and kidney allograft failure/rejection for weekend (defined as Frid

263 for 1-year mortality, rehospitalization, or allograft failure/rejection.

264 ar risk for rehospitalization, mortality, or allograft failure/rejection.

265 idence of modification of the blood pressure-allograft failure relationship by ethnicity or diabetes

266 e with ABMR histology and HLA-DSA had higher allograft failure risk (hazard ratio [HR], 7.24; 95% con

267 The reasons for kidney allograft failure subsequent to pancreas after kidney (P

268 g transplant are suboptimal owing to chronic allograft failure termed bronchiolitis obliterans syndro

269 ed organs had a significantly higher rate of allograft failure than locally transplanted organs in th

270 sociated with higher recipient mortality and allograft failure than other causes of brain death.

271 positive DSA (n=19) were more likely to have allograft failure than those without (P=0.02).

272 ated to their recipients had higher rates of allograft failure than transplants from donors unrelated

273 aimed to quantify the damage after composite allograft failure to assess whether retransplantation is

274 aving the role of elevated blood pressure in allograft failure unclear.

275 was 0.99 (+/- 0.20); mean observed/expected allograft failure was 1.03 (+/- 0.46).

276 Each independent predictor for allograft failure was assigned risk score (RS) points of

277 Maintenance immunosuppression after kidney allograft failure was associated with a greater incidenc

278 ospitalization with fever within 6 months of allograft failure was common, occurring in 44% of patien

279 withdraw or continue immunosuppression after allograft failure was deemed to be based most appropriat

280 n identified that the strongest predictor of allograft failure was induction without AL (P < 0.0001).

281 hipment of organs with no HLA mismatches and allograft failure was not confirmed.

282 The risk of pancreatic allograft failure was not significantly increased.

283 edication regimens is a major cause of renal allograft failure, we evaluated the stability over time

284 death or the combined risk of death or renal allograft failure were 0.7 (95% CI, 0.1-3.8) and 0.4 (95

285 sociations of D-BMI with pancreas and kidney allograft failure were assessed by multivariate Cox regr

286 Individual predictions of allograft failure were calculated using the integrative

287 an Sharing registry, long-term mortality and allograft failure were compared in recipients who underw

288 Results for death as well as death or allograft failure were generally consistent among elderl

289 Seven independent risk factors for allograft failure were identified: older recipient (haza

290 0-4.17], P = .0495) was also associated with allograft failure, whereas receiving a retransplant that

291 The clinical presentation was renal allograft failure, which eventually reversed.

292 fidence intervals [CI], 1.83-3.47; P<0.001), allograft failure with death-censored (HR, 3.17; 95% CI,

293 The adjusted rate ratio for allograft failure with induction therapy compared with c

294 The observed risk of allograft failure with right-sided LDN was 3.8% vs. 2.5%

295 However, the low observed risk of allograft failure with right-sided nephrectomy suggests

296 ortional hazards models assessed the risk of allograft failure with these three glomerular features.

297 We examined the risks for DGF and allograft failure within 19,461 recipient pairs of the s

298 Among SPK recipients, 6% had pancreas allograft failure within 3 months (SPK,P-) and 94% had a

299 5 ratios > or = 15 were highly predictive of allograft failure within 6 months of the assay.

300 The primary outcome was allograft failure within 90 days.